Advanced Medical Corporation (AMIC) (ADMD: OTCQB) is a Kennewick,
Washington-based late stage development company engaged primarily in the development
of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications.
AMIC’s focus is on transitioning to full operations upon receipt of FDA clearance for its patented
brachytherapy cancer products.

Brachytherapy uses radiation to destroy by placing a radioactive
isotope inside or next to the treatment area. Annual sales of brachytherapy products exceed
$1 billion, about half of which are in the United States. AMIC intends to outsource material
aspects of manufacturing, distribution, sales and marketing for its products in the United
States and to enter into licensing arrangements outside of the United States, though AMIC will
evaluate its alternatives before finalizing its plans.

Since 2006, AMIC has been focused on the commercialization of medical isotope
technologies. AMIC has explored technologies for the production of medical isotopes and
medical applications of isotope technologies including a line of brachytherapy products
incorporating patented technology licensed exclusively to AMIC by Battelle Memorial
Institute, developed at Pacific Northwest National Laboratory, a leading research institute for
government and commercial customers.

AMIC’s robust intellectual property position includes exclusive rights under 15 patents
that cover manufacturing, processing and applications for medical isotopes.

A prominent team of radiochemists, scientists and engineers, collaborating worldwide
with strategic partners, including national laboratories, universities and private corporations,
lead AMIC’s development efforts. AMIC is proud to have been recognized as a leader in the
development of new isotope technologies by local, state and federal agencies.